Answers are grounded in this paper and cite their sources.
Miscarriage is the most common adverse outcome in maternal–fetal medicine, occurring in 10–20% of clinical pregnancies1. However, the total rate of pregnancy loss is difficult to estimate if cases of peri-implantation failure are taken into account. These cases are diagnosed only by urinary human chorionic gonadotropin levels greater than 0.025 ng/mL on 3 consecutive days, and their rate could be as high as 60% in the population at reproductive age2, 3. Recently, Silver et al.4 suggested replacing the more generic medical term of ‘early pregnancy loss’ with terminology based on developmental biology such as peri-implantational loss (< 5 weeks), pre-embryonic loss (5 weeks), embryonic loss (6–9 weeks) and fetal demise (10–19 weeks). Yet, the Royal College of Obstetricians and Gynaecologists (RCOG) considers 24 weeks as the upper limit for miscarriage, given that this gestational age is nowadays regarded as the limit of viability5. Miscarriage, otherwise referred to as spontaneous abortion, should be considered a clinical event, consisting of all losses beyond 5 weeks of gestational age. In this commentary, given that we deal with clinically diagnosed pregnancy, our preference is to use the term ‘miscarriage’. Regarding a woman's total number of miscarriages, a distinction is made between sporadic (one) and recurrent (at least two) miscarriage. Risk factors for miscarriage have been described extensively. Data extracted from national Danish registries encompassing 15 years established that risk of miscarriage increases with maternal age. Taking into account only miscarriages leading to hospital admissions, an overall rate of 11% was observed, ranging from 9% at 22 years to 84% by 48 years6. The risk of miscarriage, as well as being age-dependent, is reported to depend on previous reproductive history and parity in the preceding 10 years6, 7. It appears that in women with no previous history of miscarriage, there is a slightly higher risk among parous, as compared to nulliparous, women. Conversely, in women with a history of miscarriage, this tendency is reversed, with a higher risk among nulliparous women. In relation to paternal age, the effect is unclear due to a multitude of confounding factors. It seems, however, that advanced paternal age over 50 years accounts for double the risk of late fetal loss8. Recently, prediction of miscarriage at 6–10 weeks and 11–13 weeks has been attempted using maternal and pregnancy characteristics. At 6–10 weeks, miscarriage can be predicted using a combination of maternal characteristics (advanced age, African racial origin, and cigarette smoking), pregnancy complications (vaginal bleeding) and ultrasound findings (increased yolk sac diameter and decreased gestational sac diameter, fetal heart rate and crown–rump length (CRL))9. The same group also investigated several models combining risk factors at 11–13 weeks to determine the risk of miscarriage. The risk increased with certain maternal factors (higher age and weight, African racial origin, previous miscarriages or stillbirths, pre-existing diabetes mellitus and conception with ovulation induction) and with abnormal first-trimester screening markers (low pregnancy-associated plasma protein-A levels, increased nuchal translucency thickness and reversed ductus venosus A-wave)10. A novel approach for the prediction of miscarriage, presented in the current issue of this Journal, is based on the timely recognition of failed placentation in pregnancies without potential to evolve11. Reduced trophoblast volume and growth during the first trimester (6–12 weeks), assessed by three-dimensional volumetric ultrasound, is particularly evident at 6–8 weeks. These findings are anticipated in autosomal trisomies except for trisomy 21, given that a small placental volume has been reported for trisomies 13 and 18 at 11–13 weeks12. However, the extent of failed placentation in euploid pregnancy loss remains unknown. Interestingly, when a first pregnancy is complicated by miscarriage, there is an independent increased risk of adverse perinatal outcome in the subsequent pregnancy. Specifically, there is increased risk of premature rupture of membranes, preterm delivery, growth restriction, pre-eclampsia and delivery by Cesarean section13. Ultrasound is the method of choice for the diagnosis of early embryo demise. A recent editorial by Thilaganathan summarizing the latest data urges clinicians to establish standard reference sonographic criteria for accurate diagnosis of miscarriage14. The guidelines issued by RCOG in 20065 and by the American College of Radiology in 200915 had discordant recommendations regarding whether to consider diagnostic: a) an ‘empty sac’ diameter of 16 or 20 mm; and b) an embryonic CRL of 5 or 6 mm without cardiac activity. Abdallah et al. demonstrated that 4.4% and 0.5% of continuing pregnancies are misdiagnosed as miscarriages with an empty gestational sac diameter of 16 and 20 mm, respectively. Similarly, there is an 8.3% false-positive rate if miscarriage is diagnosed by a 5-mm CRL cut-off for embryos with an absent heart beat. Thus, the authors suggest using a 25-mm gestational sac and a 7-mm CRL as safer cut-offs16. The same group also suggests that, at a follow-up scan a week later, failure to visualize a yolk sac or embryo, rather than slow growth of gestational sac or CRL, is associated with miscarriage17. Furthermore, the range of interobserver limits of agreement in mean sac diameter and CRL evaluated by transvaginal ultrasound, as reported by Pexsters et al.18, revealed measurement discrepancies and possible diagnostic error. Thus, there is a chance of accidental termination of desired pregnancies when measurements approach the decision-making cut-offs. Immediately following this evidence, the RCOG/National Institute for Health and Clinical Excellence (NICE) guidance for early pregnancy loss was revised19; the new recommendations establish a diagnosis of miscarriage by transvaginal ultrasound if there is an empty gestational sac measuring ≥ 25 mm or a fetal pole with no heart beat measuring ≥ 7 mm. In addition, a second opinion or a repeat scan performed in a week's time is strongly recommended. In any case, a cautious approach is advised to avoid misdiagnosis19. The emotional impact of miscarriage, although generally underestimated by clinicians, can be as important as that experienced in second-trimester termination of pregnancy. Depressive and anxiety symptoms and disorders following miscarriage have been the focus of research in the last decade. Lee et al.20 assessed separately the frequency of anxiety and depressive symptoms occurring after spontaneous miscarriage and concluded that, of the two, the prevalence of anxiety is significantly higher. A recent longitudinal study by Lok et al.21 provided emerging evidence regarding depression symptomatology in women who experienced miscarriage. They demonstrated that although psychological morbidity decreases over time, a significant proportion of these women are still distressed after 1 year. Furthermore, delayed depression was also noted in the group of women who were initially less distressed21. Women who have miscarried also appear to be at risk of anxiety stress disorders such as obsessive–compulsive disorder, acute-stress disorder or post-traumatic stress disorder, with reported prevalence ranging from 15% to 25% up to 4–6 months following miscarriage22, 23. Long-term psychological implications of first-trimester pregnancy loss have not been explored extensively in the literature and consequently reports are equivocal21, 24, 25. The risk of a subsequent pregnancy complicated by psychological morbidity in women who have miscarried needs to be investigated further. Longitudinal studies are warranted to define if these patients are more likely to suffer from overt post-traumatic symptoms in need of treatment or postnatal depression. In any case, timely diagnosis and follow-up of these cases will ensure delivery of appropriate care. Healthcare practitioners should be informed and trained in dealing with psychological morbidity following a miscarriage. The RCOG and the European Society for Human Reproduction Special Interest Group for Early Pregnancy are even encouraging a new revised terminology for events related to miscarriage in order to alleviate the negative impact some terms could exert on patients. For example, when counseling patients, inadvertent use of terms such as ‘abortion’ and ‘pregnancy failure’ should be avoided, and replaced by the term ‘miscarriage’, while ‘blighted ovum’ could be replaced by the term ‘delayed miscarriage’5, 26. Several etiologies for first-trimester miscarriage have been described, including chromosomal abnormalities, hormonal imbalances, immunological disorders, uterine malformations and environmental exposures27. Ultrasound has contributed mainly to diagnosis, adding little to establishing the etiology of miscarriage, either sporadic or recurrent. Recently, Angiolucci et al.28 attempted to identify ultrasound features suggestive of aneuploidy: miscarriage due to trisomy 22 was characterized mostly by an enlarged yolk sac and smaller embryos correlated with monosomy X, while normal ultrasound findings correlated with trisomy 21. Historically, histopathology has been the test available to evaluate a miscarriage. However, pathology studies of placental and embryonic tissue, beyond diagnosing molar and excluding ectopic pregnancies, are far from conclusive regarding the etiology of miscarriage29. Since more than half of miscarriages are due to chromosomal anomalies, and these differ in their recurrence patterns, chromosomal analysis should be offered as soon as miscarriage is diagnosed29-31. The benefits of recognizing the pathology underlying pregnancy failure are obvious. Yet, despite the extensive work-up following stillbirth, only histopathology is commonly offered for evaluation of miscarriage. We recently published a study carried out in our center, in which all women miscarrying from 2007 onwards were offered placental karyotyping30. The uptake was high, and we found a 65% rate of chromosomal anomaly in our series, with a similar spectrum between pre-embryonic (empty sac) and embryonic miscarriages. Pre-embryonic pregnancy losses occur at an earlier gestational age than do miscarriages due to viable trisomies (trisomies 13, 18 and 21) and monosomy X (Turner syndrome), i.e. neither viable trisomies nor monosomy X are responsible for pre-embryonic miscarriages. The information provided by cytogenetic studies was valuable for parental and future reproductive counseling, since different types of chromosomal anomalies have different recurrence patterns. For instance, inherited unbalanced structural anomalies have the highest risk of recurrence, autosomal trisomies also carry some risk, but other types are unlikely to recur30. Thus, chromosomal analysis may provide an answer to common questions such as ‘Why did it happen to me?’ and ‘Will it happen again?’. These answers helped to reduce our patients' anxiety and enabled them to deal better with bereavement and grieving following pregnancy loss32. As already mentioned, chromosomal anomalies account for the vast majority of early pregnancy losses29-31. When compared with analysis of products of conception, chorionic villus sampling (CVS) is more successful in achieving a cytogenetic result. It is therefore crucial to obtain placental tissue before any treatment commences. Inaccuracy of cytogenetic analysis or failure to deliver results may be due to unsuccessful culture growth, microbial contamination or maternal cell contamination33. The semi-direct method for chorionic villi overcomes these limitations, since omitting culture eliminates the potential for maternal contamination. Occasionally, metaphase samples cannot be obtained, and it is for this reason that other cytogenetic and molecular tests have been introduced. Fluorescence in-situ hybridization (FISH) is a rapid test of uncultured material that allows determination of ploidy status and chromosomal reorganizations, but the obtained information is limited by the choice of probe used34. Quantitative fluorescent polymerase chain reaction (QF-PCR) is a rapid molecular test that diagnoses mosaicism, maternal cell contamination and partial or complete hydatidiform mole (coupled with a maternal sample), but again the number of analyzed chromosomes is limited to between five and ten35. Non-invasive prenatal testing (NIPT), using cell-free fetal DNA (cffDNA) in maternal blood, does not appear to have a role in pregnancy loss, although some trophoblast activity may persist after fetal demise. Besides NIPT testing only five chromosomes, cffDNA (originally from placental tissue) is expected to present a low ‘fetal fraction’ in miscarriages before 10 weeks36. Another new method of chromosomal analysis covering the whole genome is array comparative genomic hybridization (array-CGH), with or without single nucleotide polymorphism (SNP) testing. Array-CGH detects aneuploidy and unbalanced structural rearrangements, as well as DNA gains and losses less than 10 Mbp in size, which go undetected by karyotyping. However, balanced translocations and many polyploidies remain undetected37, 38. When applied to products of conception, array-CGH has been shown to detect de-novo copy number changes in 13% of cases in which cytogenetic testing (i.e. karyotype) was normal or not available39. SNP microarrays differ from array-CGH in their ability to identify maternal contamination and uniparental disomy38. Although costs may still be higher and laboratory experience lower compared with conventional karyotyping, there is evidence that, nowadays, array-CGH with SNP is the method of choice, after maternal cell contamination, polyploidy and partial/complete hydatidiform mole have been ruled out by a normal QF-PCR result40. Present strategies in invasive procedure training are not based on a general consensus. The current requirements for increasing numbers of clinicians performing invasive procedures in prenatal diagnosis have compromised training standards41. Furthermore, both the necessity to acquire these technical skills in real patients and the consideration that in some cases these diagnostic procedures could be the last chance for a patient to make crucial decisions make training even more complicated. This is certainly the case regarding CVS training. The introduction of CVS before evacuation in the management of miscarriage may prove valuable to the training process. Trainees will acquire more experience by increasing the number of procedures performed without the extra psychological pressure of interfering with a viable pregnancy. Historically, use of the simplistic 1% approach (‘once an anomaly, always an invasive procedure’) to estimate the recurrence risk was widespread after a chromosomal anomaly diagnosed in a viable pregnancy. In reality, a more refined definition of the recurrence risk in subsequent pregnancies can be attempted, estimating the excess risk for both homo- (same) and hetero- trisomy in women with a previous pregnancy by autosomal chromosomal studies presented models to the recurrence risk for such as risk morbidity and excess and were both as the between and expected The of excess risk is that it the of risk due to the previous pregnancy, independent of the risk of maternal Data from the of and that the excess risk for a subsequent trisomy pregnancy decreases with increased maternal age at the time of the trisomy pregnancy, from at 20 years to at Data from the same group encompassing reported the increased recurrence risk for both the same and different when the previous pregnancy was by trisomy 13, 18 or 13 and 18 are more likely to than is trisomy maternal age is taken into the increased risk is greater for Interestingly, et who analyzed data from and reported similar Specifically, if trisomy a previous pregnancy before years of age, the is for trisomy and for Conversely, if the maternal age is years or is for all viable pregnancies with trisomies 13 or 18 the recurrence risk by for trisomy and for other a previous pregnancy with a trisomy increases the risk by for all subsequent viable It is generally that the of maternal age and increased recurrence risk is due to during These results are in with reports from the of screening et demonstrated that a previous pregnancy, of is associated with an increased risk of future Similarly, et reported a in number of embryos after a preceding autosomal miscarriage 1% of of reproductive and has been to immunological and than half of recurrent miscarriage cases are considered after extensive work-up in the including maternal ultrasound, screening for and and parental In our during the last to all women with recurrent miscarriage we have offered CVS before evacuation of the products of In our recently published series, no in the chromosomal anomaly rate were found between sporadic and recurrent or age was found to be the only significant for the chromosomal anomaly rate increased with increased maternal age, being for women years of age and for years or However, both age no were between with sporadic and with recurrent miscarriage, these chromosomal anomaly being in women and in women. Regarding in the chromosomal anomaly in the there were more chromosomal structural anomalies in cases of recurrent compared with sporadic miscarriage In the the autosomal trisomy was given that viable trisomies (trisomies 13, 18 and 21) and autosomal had a similar in sporadic miscarriage while in recurrent miscarriage there were more than viable due to a higher proportion of pre-embryonic miscarriages in this findings are in agreement with a recent of and which that the majority of women with recurrent miscarriage are in with no underlying who have miscarriages by A case in this group of miscarriage be a with early losses and with a of aneuploidy in the most recent miscarriage. This group may account for of recurrent and of all recurrent miscarriages at years of age. The authors to identify cases of recurrent miscarriage occurring by In with this et al. the of SNP in cases of euploid recurrent They de-novo copy number and of loss of of more than 5 in half of their of recurrent miscarriage. Furthermore, has more on the etiology of this of chromosomal at in patients with recurrent pregnancy loss are by many Specifically, a of pregnancy is reported after a previous conception, of whether the aneuploidy spontaneous conception or reproductive recent and a study by et the of by due to the have research to new such as or sampling in combination with the use of which is to all chromosomal analysis could to cases of recurrent miscarriage due to chromosomal abnormalities, and and Similarly, of chromosomal structural that there is no need for parental karyotyping. the of parental in has been as only 1% of with balanced will an Historically, and has been the in the treatment of first-trimester pregnancy management is while management has been suggested by as a at a of the failed is between reported and of treatment data with treatment do not the of of similar of and future reproductive and psychological analysis mostly treatment to be this results in higher and guidance in management in cases with increased risk of or a previous of for management such as lower of and and higher of growth could up to the rate of and As an to both and medical management is suggested as a The available literature suggests that a either or is a successful treatment for early pregnancy Regarding it is reported that of or of are in achieving complete uterine evacuation in up to of patients, without It is that the high occur in i.e. nulliparous women or in with lower and medical compared with delayed medical treatment following a of the need for In with this evidence, the use of of with and treatment is suggested in cases of failure of previous management or when clinically of the different treatment could be by accurate of case, to into embryonic or fetal Yet, there is still for regarding the management of miscarriage and at all of patients' In miscarriage is a that can with The of guidelines for clinical is not only of the emotional impact of miscarriage, but also of common during reproductive age. of spontaneous first-trimester miscarriage and continuing discrepancies in diagnosis and treatment have clinicians to focus on the delivery of and more The recently issued RCOG and guidelines have miscarriage diagnostic criteria to an empty gestational sac ≥ 25 mm or a fetal pole ≥ 7 mm with no heart beat. is given to diagnosis a second opinion a repeat scan in a week's miscarriage is clinicians should management on of management as the but other should be explored when of the high prevalence of chromosomal anomalies in first-trimester loss, was considered However, chromosomal studies provide valuable information the of miscarriage, as well as a recurrence risk estimate for the Thus, CVS could be offered to reduce the high of unsuccessful karyotyping, particularly when array-CGH is not recurrence risk can be obtained for both and to maternal age. recurrence risk should be regarded as the clinical of an invasive procedure after any viable chromosomal anomaly in a previous pregnancy. In the of recurrent miscarriage, chromosomal studies of the miscarried pregnancy rather than of the are more and may testing. in to identify as a of recurrent miscarriage. The time has to consider first-trimester miscarriage not as a but as a adverse on in management and counseling, future research will a more treatment of women who experience miscarriage.
No takes yet. Share an insight, caveat, or question.
Borrell et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: